Transforming Growth Factor- β1 gene polymorphism and osteoporosis in postmenopausal egyptian women.
This study was performed on 138 postmenopausal osteoporosis/osteopenic women and 128 postmenopausal female control group. There was a significant statistical difference in the CC, CT and TT (T869C) genotype frequencies between the osteopenia/osteoporosis and control subjects (p value <0.001). There was a non-significant statistical difference in the CC, CT and TT (T-509C) genotype frequencies between the osteopenia/osteoporosis and control subjects (p value <0.082). There was a significant statistical difference between TT,CT and CC of (T869C) and T score, Z score and calcium of osteopenia/osteoporosis group (p value <0.001). There was a non-significant statistical difference between TT, CT and CC of (T-509C) and T score, Z score of osteopenia/osteoporosis group (p value 0.32,0.31),but there was a statistically significant difference between the three genotyping and serum calcium and creatinine (p value 0.04). Multivariate regression analysis showed that T869C polymorphism is a significant risk factor for osteopenia/ osteoporosis (OR 3.57, 95% CI= 1.56-5.67). We concluded that T869C polymorphism of the TGF-β1 gene has an impact on bone mineral density and enhancement of the susceptibility to osteopenia/osteoporosis in Egyptian women. PMID: 29208173 [PubMed - in process]
Is it considered safe for women with postmenopausal osteoporosis to take a treatment break? When is the optimal time to resume treatment?Menopause
We described palliative care as “aggressive symptom management for maximum quality of life at the present time.”The goal is to treat and remove, or reduce, symptoms that are bothering the person who is deeply forgetful. Symptoms such as pain, or problems like urinary tract infections, are handled in ways that make sense to the person living inAlzheimer ’s World.Learn More -Alzheimer ’s WorldIn the beginning of the journey, when the person is only a little forgetful, diseases and health problems are managed so that the body and mind continue to support each otherFOR MAXIMUM QUALITY OF LIFE IN THE NOW...
Conditions: Osteoporosis, Postmenopausal; Osteoporosis; Osteoporosis Vertebral; Osteoporosis Risk; Osteoporosis Fracture; Osteoporosis Localized to Spine; Osteoporosis, Age-Related; Osteoporosis Senile; Osteoporosis of Vertebrae Intervention: Drug: Abaloparatide Sponsor: Radius Health, Inc. Recruiting
It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now. Pathogenesis of Osteoporosis New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate... [Read More]
Authors: Yang A, Yu C, You F, He C, Li Z Abstract The current treatment strategies for osteoporosis (OP) involve promoting osteogenic differentiation and inhibiting adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). According to a theory of traditional Chinese medicine (TCM), the kidneys contain an "essence" that regulate bone metabolism and generate marrow. Kidney disorders are therefore considered to be a major cause of OP as per the principles of TCM, which recommends kidney-tonifying treatments for OP. The Zuogui pill (ZGP) is a classic kidney-tonifying medication that effective...
Experimental Dermatology, EarlyView.
Male osteoporosis can occur with advanced age and with hypogonadism, with increased bone resorption and/or inadequate bone formation contributing to reduced bone mass and increased fracture risk. Abaloparatide is a selective PTH receptor agonist that increases bone formation and bone mass in postmenopausal women with osteoporosis and in estrogen-deficient animals. The current study evaluated the effects of abaloparatide in orchiectomized (ORX) rats, a model of male osteoporosis. Four-month-old Sprague-Dawley rats underwent ORX or sham surgery; 8 weeks later the ORX groups exhibited relative osteopenia vs sham controls, ...
Denosumab has been successfully used for the postmenopausal osteoporosis treatment. This research is focused on the computational analysis of the effect of denosumab on bone remodeling.
Experimental Dermatology, EarlyView.